Dapagliflozin (10Mg Tab) along with standard medical therapy

DRUG7 trials

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh, Bhavya Bhavya, MD, Brigham and Women's Hospital, Shanghai Chest Hospital, Galala University

Conditions

AnemiaAscites HepaticAtrial Fibrillation (AF)Cardiovascular CalcificationChronic Kidney DiseaseCirrhosisDiabete Type 2Lupus Nephritis (LN)

Phase 1

Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis

Active, not recruitingNCT07678203

Hospital Civil Juan I. MenchacaChronic Kidney Disease, Lupus Nephritis (LN), SGLT 2 Inhibitors +1

Start: 2026-05-28End: 2027-02-26Target: 30Updated: 2026-07-01

Phase 2

Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT

Post Graduate Institute of Medical Education and Research, ChandigarhAscites Hepatic, Cirrhosis

Start: 2021-09-03End: 2022-05-19Target: 44Updated: 2021-09-05

Phase 3

SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

CompletedNCT07344922

Mansoura UniversityAnemia, Cardiovascular Calcification, Chronic Kidney Disease

Start: 2022-09-01End: 2023-12-01Updated: 2026-01-15

Phase 4

A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

Not yet recruitingNCT07311551

Bhavya Bhavya, MDType 2 Diabetes

Start: 2025-12-24End: 2026-12-31Target: 112Updated: 2025-12-31

Dapagliflozin in Active Lupus Nephritis

RecruitingNCT07323524

Brigham and Women's HospitalLupus Nephritis (LN)

Start: 2026-05-19End: 2030-01-01Target: 33Updated: 2026-05-26

Unknown Phase

Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

Not yet recruitingNCT07331727

Shanghai Chest HospitalAtrial Fibrillation (AF)

Start: 2026-01-01End: 2026-12-31Target: 280Updated: 2026-01-12

Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

CompletedNCT07338331

Galala UniversityDiabete Type 2, Non Alcoholic Fatty Liver

Start: 2023-04-04End: 2025-09-19Updated: 2026-08-13

Related Papers

Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study.

2024-10-099 citations